Tag: rule

SAN FRANCISCO, July 02, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 154,500 shares of the Company's common stock, effective as of July 1, 2025. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective July 1, 2025, the company granted non-qualified stock options to purchase 10,700 shares of its common stock to two new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.

BOCA RATON, FL, July 02, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced the pricing of its upsized private offering of $112.5 million aggregate principal amount of 5.5% convertible senior notes due 2030 (the “Convertible Notes”), to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

BOCA RATON, FL, July 02, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company” or “DeFi Dev Corp.”), the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), today announced the pricing of its upsized private offering of $112.5 million aggregate principal amount of 5.5% convertible senior notes due 2030 (the “Convertible Notes”), to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

FORM 8.3

FORM 8.5 (EPT/RI)

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for over 12,000 U.S. and international securities, launched the OTCID™ Basic Market, a major structural upgrade that redefines the baseline for disclosure in the over-the-counter (OTC) equities space.